Opportunities in the cancer biomarker market have evolved through a number of stages. Lucintel has found the future of this market to be promising; the cancer biomarker market is expected to grow with a CAGR of 12%. In this market, breast cancer is the largest segment by cancer type, whereas omics are largest by profiling technology.  Players can benefit from the available ... Read more

Opportunities in the cancer biomarker market have evolved through a number of stages. Lucintel has found the future of this market to be promising; the cancer biomarker market is expected to grow with a CAGR of 12%. In this market, breast cancer is the largest segment by cancer type, whereas omics are largest by profiling technology.  Players can benefit from the available ... Read more